Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Charlotte Charpentier, Bénédicte Roquebert, Olivier Delelis, Lucile Larrouy, Sophie Matheron, Roland Tubiana, Marina Karmochkine, Xavier Duval, Geneviève Chêne, Alexandre Storto, Gilles Collin, Antoine Bénard, Florence Damond, Jean-François Mouscadet, Françoise Brun-Vézinet, Diane Descamps

Antimicrobial Agents and Chemotherapy 2011 March

We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H, and T97A-N155H. Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar.

Full text links

We have located links that may give you full text access.

Show additional links to paperHide additional links to paper

PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

For the best experience, use the Read mobile app

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app